Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bögemann M:

Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM et al. N Engl J Med. (2014)

Increased survival with enzalutamide in prostate cancer after chemotherapy. Scher HI et al. N Engl J Med. (2012)

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Smith MR et al. N Engl J Med. (2018)

Search results

Items: 1 to 20 of 51

1.

[Changes in the treatment of metastatic prostate cancer-new data and open questions].

Albers P, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T, Wülfing C, De Santis M.

Urologe A. 2019 Nov 28. doi: 10.1007/s00120-019-01072-0. [Epub ahead of print] German.

PMID:
31781782
2.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group.

N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.

PMID:
31340094
3.

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.

van Strijp D, de Witz C, Heitkötter B, Huss S, Bögemann M, Baillie GS, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2019 Jun 2;2019:8107807. doi: 10.1155/2019/8107807. eCollection 2019.

4.

Erratum zu: Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag.

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Aug;58(8):924. doi: 10.1007/s00120-019-0985-3. German. No abstract available.

PMID:
31236656
5.

[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Sep;58(9):1066-1072. doi: 10.1007/s00120-019-0925-2. Review. German. Erratum in: Urologe A. 2019 Aug;58(8):924.

PMID:
31041460
6.

SPARTAN: Gezielte Analyse der Resistenzen.

Bögemann M.

Oncol Res Treat. 2019;42 Suppl 2:7. doi: 10.1159/000496366. Epub 2019 Apr 8.

7.

A Self-Fulfilling Prophecy: Comparing 177Lu-PSMA Radioligand Therapy in Taxane-Naïve Versus Posttaxane Metastasized Prostate Cancer Patients?

Rahbar K, Hofman MS, Schrader AJ, Bögemann M.

J Nucl Med. 2019 Oct;60(10):1494. doi: 10.2967/jnumed.119.228742. Epub 2019 Mar 29. No abstract available.

PMID:
30926648
8.

Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.

Seifert R, Schafigh D, Bögemann M, Weckesser M, Rahbar K.

Clin Nucl Med. 2019 Jun;44(6):e394-e395. doi: 10.1097/RLU.0000000000002543.

PMID:
30889005
9.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.

N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.

PMID:
30763142
10.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
11.

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

van Strijp D, de Witz C, Vos PC, den Biezen-Timmermans E, van Brussel A, Wrobel J, Baillie GS, Tennstedt P, Schlomm T, Heitkötter B, Huss S, Bögemann M, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2018 Jul 26;2018:5821616. doi: 10.1155/2018/5821616. eCollection 2018.

12.

Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.

Roll W, Bräuer A, Weckesser M, Bögemann M, Rahbar K.

Clin Nucl Med. 2018 Oct;43(10):755-756. doi: 10.1097/RLU.0000000000002212.

PMID:
30036254
13.

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.

Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061. doi: 10.1007/s00259-018-4089-x. Epub 2018 Jul 20.

14.

[Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].

Schostak M, König F, Bögemann M, Goebell P, Hammerer P, Machtens S, Schwentner C, Thomas C, von Amsberg G, von Rundstedt FC, Heidenreich A.

Urologe A. 2018 Jul;57(7):813-820. doi: 10.1007/s00120-018-0680-9. German.

PMID:
29808368
15.

18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.

Rahbar K, Afshar-Oromieh A, Bögemann M, Wagner S, Schäfers M, Stegger L, Weckesser M.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1329-1334. doi: 10.1007/s00259-018-3989-0. Epub 2018 Mar 14.

PMID:
29541812
16.

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.

Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, Wardelmann E, Hartmann W, Rahbar K, Huss S.

Oncotarget. 2018 Jan 4;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 9.

17.

Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.

Rahbar K, Weckesser M, Ahmadzadehfar H, Schäfers M, Stegger L, Bögemann M.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077. doi: 10.1007/s00259-018-3952-0. Epub 2018 Feb 14. No abstract available.

PMID:
29445927
18.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

19.

Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods.

Bernemann C, Steinestel J, Humberg V, Bögemann M, Schrader AJ, Lennerz JK.

BJU Int. 2018 Aug;122(2):219-226. doi: 10.1111/bju.14146. Epub 2018 Feb 14.

20.

Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, Stegger L, Weckesser M, Schäfers M, Rahbar K.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):860-877. doi: 10.1007/s00259-017-3922-y. Epub 2018 Jan 15. Review.

PMID:
29335762

Supplemental Content

Loading ...
Support Center